Barcavir 1 mg
Entecavir
Category: Tablet
Manufacturer: Incepta Pharmaceuticals Ltd.
Allopathic
MFG. Licence No. Biological
193
MFG. Licence No. Non-Biological
108
Address
Zirabo, Savar, Dhaka Dewan Idris Road, Bara Rangamatia
Price: 900.0 ৳
10's pack
Medicine Selling service is not available yet.
Related Medicines
Entecavir is indicated for the treatment of chronic hepatitis B virus infection in adults and pediatric patients 2 years of age and older with evidence of active viral replication and either evidence of persistent elevation in serum aminotransferases (ALT or AST) or histologically active disease.
Hepatic viral infections (Hepatitis B)
Entecavir is a guanosine nucleoside analogue with potent and selective activity against HBV polymerase. For pharmacological action it is phosphorylated to the active triphosphate (TP) form. Entecavir triphosphate functionally inhibits all 3 activities of the viral polymerase-
Priming of the HBV polymerase,
Reverse transcription of the negative strand from the pregenomic messenger RNA
Synthesis of the positive strand HBV DNA.
Administration of Entecavir with food decreases absorption and so it should be taken in an empty stomach (at least 2 hours before or 2 hours after meal). Adult over 16 years, not previously treated with nucleoside analogues: 0.5 mg once daily.Adult over 16 years with lamivudine or telbivudine resistant chronic hepatitis B: 1 mg once daily.
Co-administration of Entecavir with Lamivudine or Adefovir dipivoxil did not result in significant drug interactions. The effects of co-administration of Entecavir with other drugs that are eliminated through renal or are known to affect renal function have not been evaluated and patients should be monitored closely for adverse events when coadministered with such drugs.
Entecavir is contraindicated in patients with previously demonstrated hypersensitivity to Entecavir or any component of the product.
The most common adverse events are headache, fatigue, dizziness and nausea.
Use in pregnancy: There are no adequate and well-controlled studies in pregnant women. Entecavir should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.Use in lactation: It is not known whether Entecavir is excreted in human milk. Mothers should be instructed not to breast-feed if they are taking Entecavir.
Lactic acidosis: Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases have been reported with the use of nucleoside analogues alone or in combination with antiretrovirals. Exacerbations of hepatitis after discontinuation of treatment: Severe acute exacerbations of hepatitis B have been reported in patients who have discontinued anti-hepatitis B therapy, including Entecavir.
There is no experience of Entecavir overdosage reported in patients. Healthy subjects who received up to 20 mg daily for up to 14 days and single doses up to 40 mg had no unexpected adverse events. If overdosage occurs, the patient must be monitored for evidence of toxicity and standard supportive treatment as necessary.
Keep in a dry place and store below 30°C. Protect from light and keep out of the reach of children.
Hepatic viral infections (Hepatitis B)
By competing with the natural substrate deoxyguanosine triphosphate, entecavir functionally inhibits all three activities of the HBV polymerase (reverse transcriptase, rt):
Base priming,
Reverse transcription of the negative strand from the pregenomic messenger RNA, and
Synthesis of the positive strand of HBV DNA. Upon activation by kinases, the drug can be incorporated into the DNA which has the ultimate effect of inhibiting the HBV polymerase activity.
There are no data on the effect of Entecavir on the transmission of HBV from mother to infant. Therefore, appropriate care should be taken. It is not known whether it is excreted in human milk. Mothers should be instructed not to breastfeed if they are taking Entecavir.
Samm Care